A retrospective study showed that pegcetacoplan, a complement inhibitor, may benefit patients with geographic atrophy (GA) from age-related macular degeneration. Treatment slowed the growth rate of GA lesions by 41% in comparison to clinical trials. Symptomatic patients with progressive vision loss derived the most benefit. Managing patient expectations and avoiding complications is crucial, as patients with GA differ from the exudative form of the disease. The study included patients with previous anti-VEGF therapy and both subfoveal and foveal lesions, making it widely applicable. The results were better than clinical trials, but caution is advised as the study may include cherry-picked patients with ideal compliance.
Source link
Study Indicates Who May Benefit Most From GA Treatment
